Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Rational Emotive Behavior Therapy01:24

Rational Emotive Behavior Therapy

324
Cognitive-behavioral therapies (CBTs) are grounded in the belief that our thoughts profoundly influence our emotions and actions. Advocates of CBT emphasize three core assumptions: first, that cognitions are identifiable and measurable; second, that they are central to psychological functioning; and third, that irrational or maladaptive beliefs can be replaced with rational and adaptive ones. This transformative approach to therapy has paved the way for specific models such as Albert...
324
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

780
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
780
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

590
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
590
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

765
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
765
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.3K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.3K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Beta-Blocker Discontinuation After Myocardial Infarction: A Systematic Review and Meta-Analysis.

JACC. Advances·2026
Same author

Beta-Blocker Discontinuation in Acute Heart Failure: A Systematic Review and Meta-Analysis.

JACC. Advances·2026
Same author

Transposition of the right renal artery to gastroduodenal artery for management of acute, symptomatic renovascular hypertension.

Journal of vascular surgery cases and innovative techniques·2026
Same author

How Are Deprescribing Clinical Practice Guidelines Disseminated and Implemented? A Cross-Sectional Study of International Organisational Stakeholders.

Basic & clinical pharmacology & toxicology·2026
Same author

DSM-5 Changes, COVID-19, and ADHD Diagnosis Rates in Individuals Younger Than 30 Years.

JAMA network open·2026
Same author

Continuing the Progress in Deprescribing: Learnings From the Second International Conference on Deprescribing.

Basic & clinical pharmacology & toxicology·2026
Same journal

Prevalence of Comorbid Postpartum Depression and Anxiety in Birthing Parents Seeking Treatment for Postpartum Depression: Prévalence de la présence comorbide de la dépression et de l'anxiété post-partum chez les parents ayant accouché qui ont consulté en raison de la dépression post-partum.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2026
Same journal

Healthcare Pattern of Use Before and After Initiating a Long-Acting Antipsychotic Among a Cohort of 6221 Patients With a History of Psychosis.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2026
Same journal

Clinician's Corner: Chatbots for Psychotherapy.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2026
Same journal

Understanding Illicit Prescription Painkiller Use: A Multivariable Exploration of Mental Health and Other Predictors Among Canadian University Students: Comprendre la consommation illicite d'analgésiques sur ordonnance : une analyse multivariée de la santé mentale et d'autres facteurs prédictifs chez les étudiants universitaires canadiens.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2026
Same journal

Update on ADHD genetics: A practitioner's perspective: Mise à jour sur la génétique du TDAH : le point de vue d'un praticien.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2026
Same journal

Sexsomnia: A Clinical Entity Psychiatrists Should Know About.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

39.5K

在不列颠哥伦比亚省,埃斯基塔洛普拉姆的使用增加:这是理性的和依据证据的吗?

Dionzie Ong1, Simroop Ladhar1, Thomas Perry2

  • 1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.

Canadian journal of psychiatry. Revue canadienne de psychiatrie
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

埃斯基塔洛普拉姆在重症抑郁症治疗中没有显著的疗效或安全益处,尽管它的成本更高. 这种抗抑郁药的比较没有发现有效性或副作用的有意义的差异.

关键词:
对于citalopram来说,这是一个很好的选择.抑郁 抑郁症 抑郁症 抑郁症 是一种它们是反体的反体.埃斯基塔洛普拉姆 (escitalopram) 是一种药物.选择性血清素再吸收抑制剂 选择性血清素再吸收抑制剂

更多相关视频

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.6K
Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
14:55

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

14.2K

相关实验视频

Last Updated: Jan 7, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

39.5K
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.6K
Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
14:55

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

14.2K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 临床药房 临床药房
  • 精神病学是一个精神病学.

背景情况:

  • 奇塔洛普拉姆和埃斯基塔洛普拉姆是常见的抗抑郁药物.
  • 埃斯基塔洛普拉姆在营销中被认为在有效性,安全性和作用速度方面优于西塔洛普拉姆.
  • 在加拿大,埃斯基塔洛普拉姆的价格大约是西塔洛普拉姆的两倍.

研究的目的:

  • 在不列颠哥伦比亚省评估citalopram与escitalopram的比较有效性和安全性.
  • 评估两种抗抑郁药物之间观察到的任何差异的临床意义.
  • 确定现有比较研究中的潜在偏见和局限性.

主要方法:

  • 对在不列颠哥伦比亚省最常见的9种抗抑郁药的处方数据的分析 (2005-2024年).
  • 对所有直接比较citalopram和escitalopram的研究进行系统审查.
  • 集中评估研究可靠性,差异的临床意义以及潜在的利益冲突.

主要成果:

  • 在不列颠哥伦比亚省,到2013年,埃斯基塔洛普拉姆的处方率超过了西塔洛普拉姆.
  • 审查了16项比较研究,其中许多研究显示了方法上的缺陷 (例如,缺少数据,选择性报告,制造商资金).
  • 没有研究表明抗抑郁药疗效在临床上有意义的差异;更快作用的说法是不一致的. 副作用的概况,包括QT延长风险,是相似的.

结论:

  • 与citalopram相比,埃斯基塔洛普拉姆在重大抑郁症中没有更高的疗效或安全性.
  • 埃斯基塔洛普拉姆的更高成本没有被可证明的临床优势证明是合理的.
  • 医疗保健提供者和患者在选择这些抗抑郁药时应考虑缺乏显著差异.